# Bausch Health Americas, Inc. clinical trials: 213 (2026)

ClinicalTrials.gov lists 213 trials with Bausch Health Americas, Inc. as lead sponsor, 6 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Bausch Health Americas, Inc.: 213 rows for $10.65, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/bausch-health-americas-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 213
- Recruiting or not yet: 6
- Read on: November 19, 2026

## Trials

The 25 newest of 213, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 23, 2026 | NCT07723924 | This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based... | Bausch Health Americas, Inc. | Phase 2 | Active not recruiting | Functional Constipation (FC) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723924) |
| April 13, 2026 | NCT07524946 | Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo | Bausch Health Americas, Inc. | Phase 4 | Recruiting | Acne Vulgaris | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07524946) |
| February 23, 2026 | NCT07428538 | Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) | Bausch Health Americas, Inc. | Phase 3 | Recruiting | Hepatitis | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07428538) |
| December 16, 2025 | NCT07285785 | Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea | Bausch Health Americas, Inc. | Phase 4 | Recruiting | Diarrhea, Gastroenteritis, Bacterial Infection, Acute Diarrhea | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285785) |
| October 9, 2025 | NCT07214272 | A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing | Bausch Health Americas, Inc. | Not applicable | Active not recruiting | Skin Resurfacing | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07214272) |
| October 3, 2025 | NCT07205107 | Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris | Bausch Health Americas, Inc. | Observational | Completed | Acne Vulgaris | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07205107) |
| September 22, 2025 | NCT07187297 | A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment | Bausch Health Americas, Inc. | Not applicable | Active not recruiting | Wrinkle, Lax Skin, Lines Skin | 164 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07187297) |
| August 4, 2023 | NCT05976802 | Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17... | Bausch Health Americas, Inc. | Phase 4 | Not yet recruiting | Ulcerative Colitis | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05976802) |
| March 28, 2022 | NCT05297448 | Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis | Bausch Health Americas, Inc. | Phase 3 | Completed | Hepatic Encephalopathy | 517 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05297448) |
| February 8, 2022 | NCT05229510 | Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via Air-Jet Nebulizer in Healthy Volunteers | Bausch Health Americas, Inc. | Phase 1 | Completed | Healthy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05229510) |
| November 24, 2021 | NCT05132231 | Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity | Bausch Health Americas, Inc. | Observational | Active not recruiting | Psoriasis | 394 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05132231) |
| October 28, 2021 | NCT05098028 | Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease | Bausch Health Americas, Inc. | Phase 2 | Completed | Sickle Cell Disease | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05098028) |
| October 8, 2021 | NCT05071716 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | Bausch Health Americas, Inc. | Phase 3 | Active not recruiting | Hepatic Encephalopathy | 524 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05071716) |
| August 30, 2021 | NCT05027282 | Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatment | Bausch Health Americas, Inc. | Not applicable | Completed | Photoaging | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05027282) |
| May 19, 2021 | NCT04892706 | Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel | Bausch Health Americas, Inc. | Phase 2 | Completed | Acne Vulgaris | 686 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04892706) |
| April 23, 2021 | NCT04857112 | Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis | Bausch Health Americas, Inc. | Phase 2 | Completed | Ulcerative Colitis | 322 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04857112) |
| September 16, 2020 | NCT04551768 | Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19 | Bausch Health Americas, Inc. | Phase 1 | Completed | COVID19 | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04551768) |
| August 28, 2020 | NCT04529811 | Randomised, Placebo-controlled Safety and Pharmacokinetics Study of Novel Rifaximin Formulations in Healthy Volunteers | Bausch Health Americas, Inc. | Phase 1 | Completed | Healthy Volunteers | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04529811) |
| April 22, 2020 | NCT04356677 | Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19\_#2 | Bausch Health Americas, Inc. | Phase 1 | Withdrawn | COVID19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04356677) |
| March 19, 2020 | NCT04314375 | Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17... | Bausch Health Americas, Inc. | Phase 4 | Recruiting | Ulcerative Colitis | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04314375) |
| January 2, 2020 | NCT04214652 | Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris | Bausch Health Americas, Inc. | Phase 3 | Completed | Acne Vulgaris | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04214652) |
| January 2, 2020 | NCT04214639 | Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris | Bausch Health Americas, Inc. | Phase 3 | Completed | Acne Vulgaris | 183 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04214639) |
| November 7, 2019 | NCT04155801 | A Study to Assess the Efficacy and Safety of Salix Probiotic Blend in Participants With Functional Gastrointestinal Disturbances | Bausch Health Americas, Inc. | Not applicable | Completed | Functional Gastrointestinal Disorders | 188 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04155801) |
| November 5, 2019 | NCT04151719 | An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer | Bausch Health Americas, Inc. | Phase 3 | Withdrawn | Pancreatic Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04151719) |
| November 4, 2019 | NCT04149587 | A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen | Bausch Health Americas, Inc. | Observational | Completed | Psoriasis | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04149587) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 39 |
| Phase 2 | 42 |
| Phase 2/3 | 2 |
| Phase 3 | 83 |
| Phase 4 | 25 |
| Not applicable | 11 |
| Observational | 11 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 174 |
| Terminated | 16 |
| Active not recruiting | 8 |
| Withdrawn | 7 |
| Recruiting | 4 |
| Not yet recruiting | 2 |
| Enrolling by invitation | 1 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Acne Vulgaris | 27 |
| Psoriasis | 18 |
| Colitis, Ulcerative | 18 |
| Constipation | 15 |
| Diarrhea | 11 |
| Inflammatory Bowel Diseases | 10 |
| Opioid-Induced Constipation | 9 |
| Hepatitis C, Chronic | 6 |
| Irritable Bowel Syndrome | 6 |
| Chronic Pain | 6 |
| Hepatic Encephalopathy | 6 |
| Gastrointestinal Diseases | 5 |
| Abdominal Pain | 4 |
| Colonic Diseases | 4 |
| Gastroenteritis | 4 |
| Intestinal Diseases | 4 |
| Parkinson Disease | 3 |
| Hepatitis C | 3 |
| Arthritis, Psoriatic | 3 |
| Liver Diseases | 3 |
| Acquired Immunodeficiency Syndrome | 3 |
| Dermatitis, Atopic | 3 |
| Proctitis | 3 |
| Proctocolitis | 3 |
| Ulcer | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Haitian restaurants in the United States](https://specstream.ai/data/businesses/haitian-restaurants/united-states)
- [Executive search firms in the United States](https://specstream.ai/data/businesses/executive-search-firms/united-states)
- [Dental clinics in the United States](https://specstream.ai/data/businesses/dental-clinics/united-states)
- [Carpenters in the United States](https://specstream.ai/data/businesses/carpenters/united-states)
- [B2B signage companies in the United States](https://specstream.ai/data/businesses/b2b-signage-companies/united-states)
- [Air duct cleaning companies in the United States](https://specstream.ai/data/businesses/air-duct-cleaning-companies/united-states)
